Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Office of Generic Drugs and Office of Pharmaceutical Quality Generics Town Hall
Session Chair(s)
Rachel Turow, JD, MPH
- Associate General Counsel, Regulatory Law and Policy | Head, U.S. Regulatory Pol
- Teva Pharmaceutical Industries Ltd., United States
Hear from leadership in FDA's Office of Generic Drugs and Office of Pharmaceutical Quality about key priorities and topics of interest for generic drug development.
Learning Objective : Identify top policy issues for generic drug development; Discuss quality and inspectional challenges for generic pharmaceutical products; Identify regulatory issues and opportunities specific to complex generics.
Speaker(s)
Panelist
William Chong, MD
- Associate Director for Clinical Affairs, Office of Generic Drugs, CDER
- FDA, United States

Panelist
Lei Zhang, PhD
- Deputy Director, Office of Research & Standards, Office of Generic Drugs, CDER
- FDA, United States
Panelist
Lisa Bercu, JD
- Regulatory Counsel, Office of Generic Drug Policy
- FDA, United States
Panelist
Ashley Boam, MS
- Director, Office of Policy for Pharmaceutical Quality, OPQ, CDER
- FDA, United States
Panelist
Susan Rosencrance, PhD
- Director, Office of Lifecycle Drug Products, OPQ, CDER
- FDA, United States
Panelist
Stelios Tsinontides, PhD, MA
- Office Director, OPMA, OPQ, CDER
- FDA, United States